Factors promoting the prolonged shedding of the pandemic (H1N1) 2009 influenza virus in patients treated with oseltamivir for 5 days

• Published in: Influenza and other respiratory viruses 2013-09, Vol.7 (5), p.833-837
• Main Authors: Ryoo, Seung M., Kim, Won Y., Sohn, Chang H., Seo, Dong W., Oh, Bum J., Lee, Jae H., Lee, Yoon S., Lim, Kyoung S.
• Format: Article
• Language: English
• Subjects: Adult; Antiviral agents; Antiviral Agents - therapeutic use; Antiviral drugs; Chronic illnesses; Diabetes; Emergency medical care; Emergency medical services; Female; H1N1 subtype; Hospitals; Humans; Hypertension; Identification methods; Immunization; Infectivity; Influenza; influenza A virus; Influenza A Virus, H1N1 Subtype - drug effects; Influenza A Virus, H1N1 Subtype - genetics; Influenza A Virus, H1N1 Subtype - isolation & purification; Influenza A Virus, H1N1 Subtype - physiology; Influenza virus; Influenza, Human - drug therapy; Influenza, Human - epidemiology; Influenza, Human - virology; Laboratories; Lung diseases; Male; Middle Aged; Observational studies; Original; Oseltamivir; Oseltamivir - therapeutic use; Pandemics; Patients; Prospective Studies; Republic of Korea - epidemiology; Respiratory diseases; RT‐PCR; Swine flu; Variables; viral shedding; Virus Shedding - drug effects; Viruses; Young Adult
• ISSN: 1750-2640; 1750-2659
• DOI: 10.1111/irv.12065

Background The duration of viral shedding is an important determinant of infectivity and transmissibility and provides vital information for effective infection prevention and control. However, few studies have evaluated viral shedding in patients admitted to hospital with 2009 H1N1 influenza and treated with oseltamivir. Objective To determine the incidence of prolonged 2009 H1N1 influenza viral shedding in patients treated for 5 days with oseltamivir and to identify factors that promote prolonged viral shedding. Methods This was a prospective, observational cohort study of 173 patients infected with 2009 H1N1 influenza (confirmed by RT‐PCR) who were admitted to isolation rooms in the emergency department of our hospital between August 25, 2009 and December 31, 2009. All of the patients were treated according to institutional protocols and received routine follow‐up RT‐PCR testing after 5 days of oseltamivir therapy. Prolonged viral shedding was defined as a positive follow‐up RT‐PCR result. Result Of the 173 patients in our cohort, 88 (50·8%) showed persistent viral shedding after oseltamivir treatment. Viral shedding was significantly prolonged if antiviral therapy was started ≥2 days after symptom onset (OR 2·74, 95% CI 1·29–5·82), if there were major comorbidities (OR 3·07, 95% CI 1·29–7·32), and/or if respiratory symptoms were still present on the day 5 of antiviral treatment (OR 4·13, 95% CI 2·10–8·11). Conclusions The presence of major comorbidities, a delay in initiating antiviral treatment, and continuing respiratory symptoms after 5 days of antiviral treatment are associated with prolonged shedding of the 2009 H1N1 influenza virus.